Cycle Pharmaceuticals has completed its acquisition of Applied Therapeutics (NASDAQ: APLD), strengthening Cycle’s position in rare metabolic and neurological diseases. The transaction, funded with cash…
February 03, 2026
January 30, 2026
FDA Approves First Combination Eye Drop for Presbyopia, Opening a New Vision-Care Market
The U.S. Food and Drug Administration has approved Yuvezzi, the first combination eye-drop therapy for presbyopia, the age-related condition that causes blurry near vision and…
The U.S. Food and Drug Administration has issued new draft guidance aimed at speeding the development and approval of treatments for multiple myeloma, a highly…
December 17, 2025
VYNE Therapeutics and Yarrow Bioscience Agree to Merge, Creating Thyroid-Focused Biotech
VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. have entered into a definitive all-stock merger agreement to combine their operations and form a new…
December 16, 2025
SandboxAQ and MapLight Therapeutics Partner to Develop AI-Discovered First-in-Class CNS Therapies
SandboxAQ and MapLight Therapeutics (Nasdaq: MPLT) have entered into a strategic collaboration aimed at discovering and developing potential first-in-class therapies for central nervous system (CNS)…
Published study supports dual-immunomodulatory approach as Coya advances COYA 302 across neuroinflammatory diseases Coya Therapeutics (Nasdaq: COYA) has announced the publication of new research in…